- Home
- SAC.WS vs YDESW Comparison
SAC.WS vs YDESW Comparison
Compare SAC.WS & YDESW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
SAC.WS
Safeguard Acquisition Corp. Warrants each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
Company Overview
Basic Information| Metric | SAC.WS | YDESW |
|---|---|---|
| Founded | N/A | N/A |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | SAC.WS | YDESW |
|---|---|---|
| Price | $0.36 | $0.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 5.0K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $0.19 |
| 52 Week High | N/A | $1.80 |
Technical Indicators
Market Signals| Indicator | SAC.WS | YDESW |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 48.06 |
| Support Level | N/A | $0.38 |
| Resistance Level | N/A | $0.58 |
| Average True Range (ATR) | 0.00 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 38.67 |
Price Performance
Historical ComparisonAbout YDESW YD Bio Limited Warrants
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.